NEUROPROTEXEON
NeuroproteXeon is a late clinical-stage pharmaceutical company developing the proprietary use of xenon gas, delivered via a patented inhalation device, to protect against brain cell death following acute neurologic injury.
NEUROPROTEXEON
Social Links:
Industry:
Life Science Medical Device Pharmaceutical
Founded:
2015-01-01
Address:
Orchard Park, New York, United States
Country:
United States
Website Url:
http://www.neuroprotexeon.com
Status:
Active
Contact:
(716) 332-7200
Technology used in webpage:
SPF SSL By Default Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS GoDaddy DNS PHP 7 GoDaddy Maintenance For WordPress
Official Site Inspections
http://www.neuroprotexeon.com
- Host name: 172.67.219.217
- IP address: 172.67.219.217
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "NeuroproteXeon"
NeuroproteXeon - Crunchbase Company Profile & Funding
NeuroproteXeon is a late clinical-stage pharmaceutical company developing the proprietary use of xenon gas, delivered via a patented inhalation device, to protect against brain cell death …See details»
NeuroproteXeon Company Profile 2024: Valuation, Investors
Information on acquisition, funding, investors, and executives for NeuroproteXeon. Use the PitchBook Platform to explore the full profile.See details»
NeuroproteXeon - LinkedIn
NeuroproteXeon is a late clinical-stage pharmaceutical company developing the proprietary use of xenon gas, delivered via a patented inhalation device, to protect against brain cell death...See details»
NeuroproteXeon Company Profile | Management and Employees …
NeuroproteXeon is a late clinical-stage pharmaceutical company developing the proprietary use of xenon gas, delivered via a patented inhalation device, to protect against brain cell death …See details»
NeuroproteXeon - Overview, News & Similar companies - ZoomInfo
NeuroproteXeon contact info: Phone number: (716) 332-7200 Website: www.neuroprotexeon.com What does NeuroproteXeon do? NeuroproteXeon is a late clinical-stage pharmaceutical …See details»
NPXe Company Profile - Office Locations, Competitors ... - Craft
NPXe (also known as NeuroproteXeon) is a pharmaceutical and drug delivery device company. It develops the proprietary use of xenon gas, delivered via a patented inhalation device, to …See details»
NeuroproteXeon - Frontcourt Group
Facilitated successful US license of NeuroproteXeon by Mallinckrodt plc (NYSE:MNK)See details»
NeuroproteXeon - Products, Competitors, Financials, Employees ...
NeuroproteXeon is a late clinical-stage pharmaceutical company focused on developing treatments for acute neurologic injuries. Use the CB Insights Platform to explore …See details»
Invero Pharma LLC Acquires Assets of Neuroprotexeon, Inc - PRWeb
Jul 6, 2021 · Invero Pharma is a late clinical-stage pharmaceutical company developing the proprietary use of xenon gas, delivered via a patented inhalation device, to protect against …See details»
BUSINESS NEWS PRESS RELEASE - inveropharma.com
Jun 29, 2021 · Invero Pharma is a late clinical-stage pharmaceutical company developing the proprietary use of xenon gas, delivered via a patented inhalation device, to protect against …See details»
News - Invero Pharma
Invero Pharma acquires assets of Neuroprotexeon [Montville, NEW JERSEY June 29, 2021] – Invero Pharma LLC announces it has acquired the assets and intellectual property of …See details»
News Detail | Mallinckrodt Pharmaceuticals
Under terms of the agreement, later today Mallinckrodt will pay $10 million upfront with cash on hand to reimburse NeuroproteXeon for certain product development costs, and gains …See details»
Short of Funding, NPXe Files for Bankruptcy and Seeks to
Dec 31, 2019 · On Monday, Buffalo, N.Y.-based NPXe, formerly known as NeuroproteXeon, filed a voluntary petition to reorganize under Chapter 11 of the Bankruptcy Code and is also …See details»
Mallinckrodt Strategic Portfolio Development NeuroproteXeon …
Oct 2, 2017 · industries in which Mallinckrodt and NeuroproteXeon operate; • The commercial success of Mallinckrodt’s products and of NeuroproteXeon’s product; • Mallinckrodt’s ability to …See details»
Protecting the Brain With Xenon Anesthesia for Neurosurgical
NeuroproteXeon’s mission is to develop xenon for clinical use to prevent acute ongoing neurological injury. M.M. has an equity stake in NeuroproteXeon through (i) founder status, (ii) …See details»
Mallinckrodt Licenses Inhaled Xenon Gas Therapy Development …
Oct 2, 2017 · Under terms of the agreement, later today Mallinckrodt will pay $10 million upfront with cash on hand to reimburse NeuroproteXeon for certain product development costs, and …See details»
Mallinckrodt licenses NeuroproteXeon’s xenon gas therapy
Oct 2, 2017 · Mallinckrodt (NYSE:MNK) has entered into a licensing agreement for development and commercialization of NeuroproteXeon’s pharmaceutical-grade xenon gas for inhalation …See details»
NeuroproteXeon Announces Publication of Xenon Study to Lessen …
Nov 28, 2017 · NeuroproteXeon, Inc. is a clinical-stage pharmaceutical/device company developing xenon to improve functional capabilities and survival in patients with Post-Cardiac …See details»
Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy
Oct 3, 2017 · Mallinckrodt plc MNK announced that it has entered into a licensing agreement with NeuroproteXeon. The agreement relates to the development and commercialization of …See details»
Xenon Gas Treatment Studied at Turku University Hospital …
Apr 12, 2017 · Xenon gas was studied at the Intensive Care Unit (ICU) of Turku University Hospital, Finland in 2009–2014 as a treatment for minimising the damage of cardiac arrest, …See details»